| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Biological Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20892
A human cell line BE, derived from an undifferentiated carcinoma of the colon, was studied for its response to the cytocidal effects of human immune interferon (IFN-
) alone and in combination with various double-stranded RNAs (dsRNAs). BE cells were moderately refractory to 3-day treatment with IFN-
(10 to 300 units/ml) where only 5 to 30% reduction in colony formation occurred. A similar exposure interval to polyriboinosinic·polyribocytidylic acid [poly(I)·poly(C)] (100 µg/ml) had no detectable effect on colony formation. In contrast, the lethal effect of the combination of IFN-
and poly(I)·poly(C) was synergistic and this regimen produced a 40 to 80% reduction in colony formation. The cytocidal effects of the combination of IFN-
with varying concentrations of the dsRNAs poly(I)·poly(C), polyriboadenylic·polyribouridylic acid [poly(A)·poly(U)], polyriboinosinic·polyribocytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(ICLC)], and mismatched dsRNA [rIm·r(C13, U)m] were also examined. The concentration of the dsRNAs producing a 50% decrease in cell viability in combination with IFN-
(100 units/ml) was 6 µg/ml for poly(I)·poly(C), 1 µg/ml for poly(A)·poly(U), 3 ng/ml for poly(ICLC), and 16 µg/ml for rIm·r(C13,U)m-DNA, RNA, and protein synthesis in IFN-
and poly(I)·poly(C)-treated cells were reduced in a dose-dependent manner. However, there were no changes in either (2',5')oligoadenylate concentrations or in ribosomal RNA transcription following treatment with IFN-
and poly(I)·poly(C). Thus, the synergism resulting from the combination of IFN-
and dsRNA appears to be mediated via another, as yet unknown, mechanism.
1 To whom requests for reprints should be addressed, at National Cancer Institute, Building 37, Room 5D02, Bethesda, MD 20892.
Received 10/ 2/85. Revised 12/ 9/85. Accepted 1/ 3/86.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |